Spots Global Cancer Trial Database for cyt387 (momelotinib)
Every month we try and update this database with for cyt387 (momelotinib) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | NCT01236638 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company |